Department of Lung Diseases, Medical University of Bialystok, Zurawia 14, Bialystok, Poland.
Adv Exp Med Biol. 2013;756:23-8. doi: 10.1007/978-94-007-4549-0_4.
Chronic obstructive pulmonary disease (COPD) is a progressive, inflammatory condition, involving airways and lung parenchyma. The disease leads to airflow limitation, and pulmonary hyperinflation, resulting in dyspnea, decreased exercise tolerance, and impaired quality of life. COPD pharmacotherapy guidelines are based on a combination of long-acting beta2-agonists (LABA), long-acting antimuscarinic agents (LAMA) and methyloxantins. Recently, indacaterol, ultralong acting beta2-agonist, has been introduced. The aim of our study was to assess the impact of indacaterol add-on therapy on lung function, exercise tolerance and quality of life of COPD patients. Thirty four COPD patients, receiving stable bronchodilator therapy were randomly allocated into two arms of add-on treatment (1:1 - indacaterol:placebo) for 3 months. Indacaterol replaced LABA in all patients receiving LABA. Spirometry, lung volumes, DLCO, St George's Respiratory Questionnaire (SGRQ) and 6 min Walk Distance (6MWD) were performed before and after therapy. We found that in the indacaterol group FEV1 did not changed significantly. However, there were significant improvements in ERV, 6MWD, and 6MWD-related dyspnea score. We also found that the degree of desaturation before and after 6MWD, and fatigue levels significantly improved in the indacaterol group. The patients' quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients.
慢性阻塞性肺疾病（COPD）是一种进行性、炎症性疾病，涉及气道和肺实质。该疾病导致气流受限和肺过度充气，导致呼吸困难、运动耐量降低和生活质量受损。COPD 药物治疗指南基于长效β2-激动剂（LABA）、长效抗胆碱能药物（LAMA）和甲基黄嘌呤的联合应用。最近，引入了长效β2-激动剂茚达特罗。我们的研究目的是评估茚达特罗附加治疗对 COPD 患者肺功能、运动耐量和生活质量的影响。34 名接受稳定支气管扩张剂治疗的 COPD 患者被随机分配到附加治疗的两个组（1:1-茚达特罗：安慰剂），治疗 3 个月。在所有接受 LABA 的患者中，茚达特罗替代了 LABA。在治疗前后进行了肺量测定、肺容积、DLCO、圣乔治呼吸问卷（SGRQ）和 6 分钟步行距离（6MWD）。我们发现，在茚达特罗组中，FEV1 没有显著变化。然而，在 ERV、6MWD 和 6MWD 相关呼吸困难评分方面有显著改善。我们还发现，在 6MWD 前后的脱氧程度和疲劳水平在茚达特罗组中显著改善。患者的生活质量在茚达特罗治疗组也得到了改善。我们得出结论，茚达特罗附加治疗对 COPD 患者有积极的影响。
